Bloodwork: what to track and why it matters

Laboratory testing is a way of checking internal organ function and metabolic markers that don't reliably announce themselves through symptoms. Liver enzymes can rise substantially before a person notices anything unusual. Hematocrit can climb into a range associated with elevated clotting risk without any subjective change in how someone feels. Kidney function can decline gradually and silently over months. This is why clinical monitoring protocols for many drug classes, including approved ones, build in scheduled lab draws rather than relying on symptom reporting alone.

Different peptide and hormone-adjacent compound categories are associated with different sets of relevant markers, based on their known or plausible mechanisms. For GLP-1 receptor agonists, the panel used in clinical research and by prescribing clinicians typically includes fasting glucose, hemoglobin A1c, a comprehensive metabolic panel (liver enzymes, kidney markers, electrolytes), and a lipid panel. GLP-1 receptor agonists such as semaglutide are associated with improved glycemic control and significant weight loss in large randomized trials, but rapid weight loss of any kind is also associated with an increased risk of gallstone formation, and some studies have noted transient changes in liver enzymes during the early titration period. Baseline values make it possible to distinguish a pre-existing condition from a change associated with treatment.

For compounds intended to stimulate the growth hormone axis (including GHRH analogs and ghrelin-receptor agonists sometimes marketed as GH secretagogues), IGF-1 is the standard downstream marker used in endocrinology because it reflects integrated GH exposure over time better than a single GH measurement, which fluctuates in pulses throughout the day. Human studies of compounds like CJC-1295 have documented dose-dependent, sustained increases in GH and IGF-1 over one to several weeks following administration, according to research published in the Journal of Clinical Endocrinology and Metabolism. Chronically elevated IGF-1 above the normal reference range for age is the kind of finding that, in clinical endocrinology, prompts further evaluation, because sustained GH/IGF-1 excess is associated with impaired insulin sensitivity and, in conditions like acromegaly, with a range of downstream health effects. Tracking fasting glucose and A1c alongside IGF-1 is standard practice for this reason.

For any compound that could plausibly affect the hypothalamic-pituitary-gonadal (HPG) axis, relevant markers include total and free testosterone, LH, FSH, and estradiol by a sensitive assay. Suppression of endogenous testosterone production is a well-documented and predictable physiological response to exogenous androgen or certain axis-modulating compounds, and low testosterone is associated with fatigue, reduced bone density, and mood changes over time in the endocrinology literature. Knowing a baseline value is what makes it possible to identify suppression if it occurs, rather than attributing symptoms to something else.

For peptides marketed for recovery or tissue repair, such as BPC-157 or TB-500, there is no single validated human biomarker, largely because there is limited human clinical trial data on these compounds at all. A 2025 systematic review in orthopaedic sports medicine screened 544 published studies on BPC-157 and found only one clinical study meeting inclusion criteria, with the remaining evidence base built from animal and preclinical models. In the absence of a specific validated marker, monitoring a basic metabolic panel, liver enzymes, and a CBC provides a general safety net for detecting unexpected reactions, alongside tracking functional measures relevant to the underlying injury, such as range of motion or pain scores.

Testing cadence matters as much as the panel itself. Comprehensive baseline testing before starting anything new establishes a personal reference point. Markers that change quickly, like liver enzymes after an acute insult, can be rechecked within days to weeks if there's a specific concern. Markers that build slowly, like A1c (which reflects roughly a three-month average of blood glucose) or IGF-1, need weeks to months to reach a new steady state, so checking too soon after starting something new mostly captures short-term noise rather than a meaningful trend. A single data point should generally be interpreted with caution; a consistent direction across two or three sequential tests carries more information.

Clinical trials use specific numeric thresholds as stopping rules precisely because relying on symptoms alone misses problems until they're more advanced. Drug-induced liver injury guidance commonly cited in hepatology (including from the American Association for the Study of Liver Diseases) uses a rise to three times the upper limit of normal in ALT or AST, particularly combined with elevated bilirubin, as a threshold warranting drug discontinuation and further workup. A hematocrit above roughly 54% is associated with increased blood viscosity and clotting risk and is a recognized indication for therapeutic phlebotomy in conditions like polycythemia. These thresholds come from decades of accumulated clinical experience across drug classes, not from data on any single research peptide, but the underlying physiological principle, that certain lab changes precede symptoms and carry real risk, generalizes across contexts.

Evidence quality: for the physiological mechanisms discussed here, such as A1c reflecting long-term glucose control, IGF-1 reflecting integrated GH exposure, and hematocrit correlating with clotting risk, the evidence is strong human evidence drawn from decades of endocrinology and hematology research. For how specific unregulated research peptides affect these markers in humans, the evidence is limited to early human evidence at best (for compounds like semaglutide, which has extensive trial data) and mostly animal or mechanistic evidence for less-studied compounds like BPC-157 and TB-500.

Limitations worth stating plainly: reference ranges and stopping thresholds were developed primarily in the context of studied pharmaceuticals, not in the context of unregulated research compounds of variable purity, so applying them to a self-directed protocol involves some extrapolation. Individual variation in how any given compound affects labs is not well characterized outside of trial populations. In practical terms, a rising or clearly abnormal trend, especially one that persists across repeated tests, is a reasonable prompt to pause and seek a clinical evaluation rather than to wait for symptoms to confirm a problem that lab work already flagged.

It's also worth being specific about what a single abnormal marker does and doesn't tell you when a peptide is involved. An isolated elevated liver enzyme drawn after a hard training session, a night of drinking, or a course of an unrelated over-the-counter medication like acetaminophen can look identical on paper to an elevation caused by something else entirely. Distinguishing between these possibilities generally requires more than the number itself: a repeat test after avoiding the likely confounder, a look at the full panel rather than one value in isolation, and, where the picture stays unclear, an actual clinical evaluation. Attributing every abnormal value to whatever compound is currently being used, without ruling out more mundane explanations first, tends to produce both false alarms and missed real problems.

Purity and sourcing add another layer of uncertainty specific to research peptides that doesn't apply to FDA-approved drugs. Because these compounds are not manufactured under the same regulatory oversight, contamination, incorrect concentration, or the presence of unlisted byproducts are documented realities in independent testing of some research-peptide products. That means an unexpected lab change could, in principle, reflect something in the product other than the peptide itself, which is a variable that is essentially uncharacterizable from the outside and is one more reason why baseline testing and a cautious, trend-based approach to interpretation matter more here than they would with a pharmaceutical-grade product with a known, consistent formulation.

Putting this together, a reasonable approach is to treat lab monitoring as an ongoing practice rather than a one-time checkbox: a real baseline before starting anything, a follow-up panel timed to when the relevant marker would be expected to have moved, and a plan for what specific finding would prompt stopping and seeking care, decided in advance rather than negotiated in the moment when a number looks concerning. That kind of structure doesn't eliminate risk, but it converts an otherwise invisible process into something that can actually be observed and acted on before a problem becomes symptomatic.